Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Isenberg

Showing results (211-220 of 280) with videos related to

Pageof 28
Sort By:
Annals of the Rheumatic Diseases|March 28, 2024
Correspondence on 'Current myositis clinical trials and tribulations' by Saygin <i>et al</i>Sofia Ferreira Azevedo, Antonia Valenzuela, Cristian Alejandro Benitez, et al.
Rheumatology (Oxford, England)|October 3, 2014
Proof-of-concept study demonstrating the pathogenicity of affinity-purified IgG antibodies directed to domain I of β2-glycoprotein I in a mouse model of anti-phospholipid antibody-induced thrombosisCharis Pericleous, Patricia Ruiz-Limón, Zurina Romay-Penabad, et al.
Cell Reports. Medicine|January 18, 2023
Inactive disease in patients with lupus is linked to autoantibodies to type I interferons that normalize blood IFNα and B cell subsetsHannah F Bradford, Liis Haljasmägi, Madhvi Menon, et al.
Arthritis and Rheumatism|April 3, 2008
Familial clustering of non-nuclear autoantibodies and C3 and C4 complement components in systemic lupus erythematosusSaowalak Hunnangkul, Dorothea Nitsch, Benjamin Rhodes, et al.
Arthritis and Rheumatism|December 1, 2007
British Isles Lupus Assessment Group 2004 index is valid for assessment of disease activity in systemic lupus erythematosusChee-Seng Yee, Vernon Farewell, David A Isenberg, et al.
Rheumatology (Oxford, England)|February 26, 2010
Numerical scoring for the BILAG-2004 indexChee-Seng Yee, Lynne Cresswell, Vernon Farewell, et al.
Rheumatology (Oxford, England)|January 20, 2011
The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patientsChee-Seng Yee, Vernon T Farewell, David A Isenberg, et al.
Frontiers in Immunology|December 21, 2018
Low Percentage of Signal Regulatory Protein α/β<sup>+</sup> Memory B Cells in Blood Predicts Development of Anti-drug Antibodies (ADA) in Adalimumab-Treated Rheumatoid Arthritis PatientsLaura Magill, Marsilio Adriani, Véronique Berthou, et al.
Rheumatology (Oxford, England)|January 18, 2020
A reverse translational study on the effect of rituximab, rituximab plus belimumab, or bortezomib on the humoral autoimmune response in SLELaura S van Dam, Zgjim Osmani, Sylvia W A Kamerling, et al.
Rheumatology (Oxford, England)|August 22, 2012
The BILAG-2004 systems tally--a novel way of representing the BILAG-2004 index scores longitudinallyChee-Seng Yee, Caroline Gordon, David A Isenberg, et al.
Pageof 28

Showing results (211-220 of 280) with videos related to

Sort By:
Pageof 28
Annals of the Rheumatic Diseases|March 28, 2024
Correspondence on 'Current myositis clinical trials and tribulations' by Saygin <i>et al</i>Sofia Ferreira Azevedo, Antonia Valenzuela, Cristian Alejandro Benitez, et al.
Rheumatology (Oxford, England)|October 3, 2014
Proof-of-concept study demonstrating the pathogenicity of affinity-purified IgG antibodies directed to domain I of β2-glycoprotein I in a mouse model of anti-phospholipid antibody-induced thrombosisCharis Pericleous, Patricia Ruiz-Limón, Zurina Romay-Penabad, et al.
Cell Reports. Medicine|January 18, 2023
Inactive disease in patients with lupus is linked to autoantibodies to type I interferons that normalize blood IFNα and B cell subsetsHannah F Bradford, Liis Haljasmägi, Madhvi Menon, et al.
Arthritis and Rheumatism|April 3, 2008
Familial clustering of non-nuclear autoantibodies and C3 and C4 complement components in systemic lupus erythematosusSaowalak Hunnangkul, Dorothea Nitsch, Benjamin Rhodes, et al.
Arthritis and Rheumatism|December 1, 2007
British Isles Lupus Assessment Group 2004 index is valid for assessment of disease activity in systemic lupus erythematosusChee-Seng Yee, Vernon Farewell, David A Isenberg, et al.
Rheumatology (Oxford, England)|February 26, 2010
Numerical scoring for the BILAG-2004 indexChee-Seng Yee, Lynne Cresswell, Vernon Farewell, et al.
Rheumatology (Oxford, England)|January 20, 2011
The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patientsChee-Seng Yee, Vernon T Farewell, David A Isenberg, et al.
Frontiers in Immunology|December 21, 2018
Low Percentage of Signal Regulatory Protein α/β<sup>+</sup> Memory B Cells in Blood Predicts Development of Anti-drug Antibodies (ADA) in Adalimumab-Treated Rheumatoid Arthritis PatientsLaura Magill, Marsilio Adriani, Véronique Berthou, et al.
Rheumatology (Oxford, England)|January 18, 2020
A reverse translational study on the effect of rituximab, rituximab plus belimumab, or bortezomib on the humoral autoimmune response in SLELaura S van Dam, Zgjim Osmani, Sylvia W A Kamerling, et al.
Rheumatology (Oxford, England)|August 22, 2012
The BILAG-2004 systems tally--a novel way of representing the BILAG-2004 index scores longitudinallyChee-Seng Yee, Caroline Gordon, David A Isenberg, et al.
Pageof 28